Can Paxlovid (nirmatrelvir + ritonavir) be used in a patient with cirrhosis, and what dosing is appropriate for Child‑Pugh A versus Child‑Pugh B/C disease?

Use of Paxlovid in Cirrhosis

Paxlovid can be used in patients with Child-Pugh A or B cirrhosis without dose adjustment, but is not recommended in Child-Pugh C cirrhosis due to lack of safety data. 1

Dosing by Child-Pugh Class

Child-Pugh A (Mild Hepatic Impairment)

• Standard dosing of nirmatrelvir/ritonavir 300/100 mg twice daily for 5 days is appropriate without any dose adjustment. 1, 2
• A Phase 1 study demonstrated that nirmatrelvir systemic exposure and maximum plasma concentrations were comparable between patients with normal hepatic function and those with moderate hepatic impairment when co-administered with ritonavir. 2
• The primary elimination route for nirmatrelvir when given with ritonavir is renal excretion of unchanged drug, not hepatic metabolism, which supports safe use in hepatic impairment. 2

Child-Pugh B (Moderate Hepatic Impairment)

• Standard dosing of nirmatrelvir/ritonavir 300/100 mg twice daily for 5 days is appropriate without any dose adjustment. 1, 2
• Pharmacokinetic data specifically evaluated moderate hepatic impairment (Child-Pugh B) and found no clinically significant changes in nirmatrelvir exposure, supporting the no-adjustment recommendation. 2
• The FDA label explicitly states that no dosage adjustment is needed for moderate hepatic impairment. 1

Child-Pugh C (Severe Hepatic Impairment)

• Paxlovid is not recommended for use in patients with Child-Pugh C cirrhosis because no pharmacokinetic or safety data are available in this population. 1
• This is a data gap rather than a proven contraindication, but the absence of safety information in severely decompensated patients warrants avoidance. 1
• If treatment is deemed absolutely necessary in a Child-Pugh C patient with no alternatives, this would be off-label use requiring intensive monitoring for adverse effects and hepatic decompensation. 1

Key Mechanistic Considerations

• Ritonavir inhibits CYP3A4, which shifts nirmatrelvir elimination from hepatic metabolism to predominantly renal excretion, making hepatic impairment less relevant to nirmatrelvir clearance. 2
• This pharmacokinetic profile explains why hepatic impairment has minimal impact on nirmatrelvir exposure when co-administered with ritonavir. 2
• However, ritonavir itself is metabolized hepatically, and historical data from HIV treatment show that protease inhibitors can have higher exposures in severe hepatic impairment. 3

Renal Function Considerations in Cirrhotic Patients

• If the cirrhotic patient also has moderate renal impairment (eGFR 30-60 mL/min), reduce the dose to nirmatrelvir/ritonavir 150/100 mg twice daily. 1, 4
• If the patient has severe renal impairment (eGFR <30 mL/min), reduce to nirmatrelvir/ritonavir 150/100 mg once daily. 1
• Nirmatrelvir systemic exposure increases significantly with declining renal function (187% in moderate impairment, 304% in severe impairment compared to normal function), necessitating dose reduction. 4
• Many cirrhotic patients have concurrent renal dysfunction (hepatorenal syndrome or chronic kidney disease), making renal function assessment critical before prescribing. 4

Critical Drug Interaction Monitoring

• Ritonavir is a potent CYP3A4 inhibitor responsible for approximately 60% of drug metabolism, creating significant potential for drug-drug interactions in cirrhotic patients who are typically on multiple medications. 5
• Review all concurrent medications for contraindications, particularly statins, antiarrhythmics, sedatives, and immunosuppressants that may require temporary discontinuation or dose adjustment. 5
• Consider stopping non-essential interacting medications (such as statins) for the 5-day Paxlovid treatment course if clinically appropriate. 3

Common Pitfalls to Avoid

• Do not assume all antivirals are contraindicated in cirrhosis—unlike interferon-based regimens which are absolutely contraindicated in Child-Pugh C, Paxlovid's renal elimination pathway makes it safer in hepatic impairment. 3, 6, 1
• Do not overlook concurrent renal impairment in cirrhotic patients, as this requires dose reduction even when hepatic function alone would not. 1, 4
• Do not prescribe Paxlovid without a comprehensive medication review, as ritonavir's CYP3A4 inhibition can cause dangerous interactions with commonly used drugs in cirrhotic patients. 5
• Do not use Paxlovid in Child-Pugh C patients unless absolutely no alternative exists and the benefit clearly outweighs the unknown risk. 1